Chimerix, Inc. (NASDAQ:CMRX) is reporting second quarter financial results on Monday 10th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, CMRX is expected to report 2Q20 loss of $ 0.17 per share from revenue of $ 1.06 million.
For the full year, analysts anticipate top line of $ 4.40 million, while looking forward to loss of $ 0.75 per share bottom line.
Previous Quarter Performance
Chimerix, Inc. recorded loss for the first quarter of $ 0.17 per share, from the revenue of $ 1.24 million. Wall street analysts are predicting, CMRX to report 1Q20 loss of $ 0.15 per share from revenue of $ 1.75 million. The bottom line results missed street analysts by $ 0.02 or 13.33 percent, at the same time, top line results fell short of analysts by $ 0.51 million or 29.14 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Chimerix, Inc.
Stock Performance
According to the previous trading day, closing price of CMRX was $ 3.41, representing a 186.55 % increase from the 52 week low of $ 1.19 and a 12.34 % decrease over the 52 week high of $ 3.89.
The company has a market capital of $ 211.18 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CMRX” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Chimerix, Inc. will be hosting a conference call at 8:30 AM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.chimerix.com
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The companys lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside for the treatment of norovirus; and CMX157, a nucleoside analog for the treatment of HIV and hepatitis B virus infection.
